Acceleron, Celgene score second win with latest luspatercept readout

Acceleron Pharma Inc. (NASDAQ:XLRN) climbed $1.36 to $48.76 July 10 after it and partner Celgene Corp. (NASDAQ:CELG) said luspatercept (ACE-536) met the primary endpoint in the Phase III BELIEVE study to treat beta-thalassemia. The companies are planning regulatory submissions for the candidate in the U.S. and EU in 1H19.

The results come less than two weeks

Read the full 558 word article

User Sign In